Loading…
Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases
Background This study was performed to validate a scoring system published in 2008 to predict the survival of patients receiving whole-brain radiotherapy (WBRT) alone for brain metastases. Methods The scoring system included four independent prognostic factors: age, performance status, extracranial...
Saved in:
| Published in: | Strahlentherapie und Onkologie 2013-05, Vol.189 (5), p.364-366 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c372t-c6c43c15a1cfb02548af539efd4b9e4db8339fbd0e7e72f986699977d884a12d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c372t-c6c43c15a1cfb02548af539efd4b9e4db8339fbd0e7e72f986699977d884a12d3 |
| container_end_page | 366 |
| container_issue | 5 |
| container_start_page | 364 |
| container_title | Strahlentherapie und Onkologie |
| container_volume | 189 |
| creator | Dziggel, L. Segedin, B. Podvrsnik, N.H. Oblak, I. Schild, S.E. Rades, D. |
| description | Background
This study was performed to validate a scoring system published in 2008 to predict the survival of patients receiving whole-brain radiotherapy (WBRT) alone for brain metastases.
Methods
The scoring system included four independent prognostic factors: age, performance status, extracranial metastases, and interval between first diagnosis of cancer and WBRT. The score for each prognostic factor was determined by dividing the 6-month survival rate (in %) by 10. The total score represented the sum of the scores for each prognostic factor. Total scores ranged from 9–18 points, and patients were divided into four groups. In the present study, 350 new patients were evaluated in order to validate the previously developed score.
Results
In the present validation study, the 6-month survival rates were 8 % for patients with a score of 9–10 points (group A), 24 % for those with a score of 11–13 points (group B), 51 % for those with a score of 14–16 points (group C), and 82 % for those with scores of 17–18 points (group D), respectively (p |
| doi_str_mv | 10.1007/s00066-013-0308-3 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1357394990</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2984986601</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-c6c43c15a1cfb02548af539efd4b9e4db8339fbd0e7e72f986699977d884a12d3</originalsourceid><addsrcrecordid>eNp1kEtLxDAQx4Mouj4-gBcJeI5OmrRpjiK-QPCi4i2kzcTtstusSdbFb2_XqngRBgZm_g_4EXLM4YwDqPMEAFXFgAsGAmomtsiES6EZaP2yTSbAlWaKl_Ue2U9pBsArqeUu2StEybUo6wnxz3beOZu70NPgqaVpFd-7dzunqQ0RqQ-RLoc39jnRHNFmdHTd5SldT8McWRNt19NoXRfyFKNdfnxZxvMCs03DYDokO97OEx597wPydH31eHnL7h9u7i4v7lkrVJFZW7VStLy0vPUNFKWsrS-FRu9ko1G6phZC-8YBKlSF13VVaa2VcnUtLS-cOCCnY-4yhrcVpmxmYRX7odJwUSqhpdYwqPioamNIKaI3y9gtbPwwHMyGrBnJmoGs2ZA1YvCcfCevmgW6X8cPykFQjII0vPpXjH-q_039BG0AhR8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1357394990</pqid></control><display><type>article</type><title>Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases</title><source>Springer Link</source><creator>Dziggel, L. ; Segedin, B. ; Podvrsnik, N.H. ; Oblak, I. ; Schild, S.E. ; Rades, D.</creator><creatorcontrib>Dziggel, L. ; Segedin, B. ; Podvrsnik, N.H. ; Oblak, I. ; Schild, S.E. ; Rades, D.</creatorcontrib><description>Background
This study was performed to validate a scoring system published in 2008 to predict the survival of patients receiving whole-brain radiotherapy (WBRT) alone for brain metastases.
Methods
The scoring system included four independent prognostic factors: age, performance status, extracranial metastases, and interval between first diagnosis of cancer and WBRT. The score for each prognostic factor was determined by dividing the 6-month survival rate (in %) by 10. The total score represented the sum of the scores for each prognostic factor. Total scores ranged from 9–18 points, and patients were divided into four groups. In the present study, 350 new patients were evaluated in order to validate the previously developed score.
Results
In the present validation study, the 6-month survival rates were 8 % for patients with a score of 9–10 points (group A), 24 % for those with a score of 11–13 points (group B), 51 % for those with a score of 14–16 points (group C), and 82 % for those with scores of 17–18 points (group D), respectively (p < 0.001). In our previous study published in 2008, the 6-month survival rates were 6 %, 15 %, 43 %, and 76 %, respectively (p < 0.001). The comparisons between each of the four prognostic groups of both series did not reveal a significant difference.
Conclusion
In this study, the 6-month survival rates of the four prognostic groups were not significantly different from those of the preceding study. This demonstrates the validity and reproducibility of this score. The score can help select the appropriate treatment for the individual patient and help design prospective trials.</description><identifier>ISSN: 0179-7158</identifier><identifier>EISSN: 1439-099X</identifier><identifier>DOI: 10.1007/s00066-013-0308-3</identifier><identifier>PMID: 23519358</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Age Distribution ; Aged ; Aged, 80 and over ; Brain Neoplasms - mortality ; Brain Neoplasms - radiotherapy ; Brain Neoplasms - secondary ; Female ; Germany - epidemiology ; Humans ; Incidence ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Radiotherapy ; Radiotherapy, Conformal - mortality ; Reproducibility of Results ; Risk Assessment - methods ; Sensitivity and Specificity ; Survival Analysis ; Survival Rate ; Treatment Outcome</subject><ispartof>Strahlentherapie und Onkologie, 2013-05, Vol.189 (5), p.364-366</ispartof><rights>Urban & Vogel 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-c6c43c15a1cfb02548af539efd4b9e4db8339fbd0e7e72f986699977d884a12d3</citedby><cites>FETCH-LOGICAL-c372t-c6c43c15a1cfb02548af539efd4b9e4db8339fbd0e7e72f986699977d884a12d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23519358$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dziggel, L.</creatorcontrib><creatorcontrib>Segedin, B.</creatorcontrib><creatorcontrib>Podvrsnik, N.H.</creatorcontrib><creatorcontrib>Oblak, I.</creatorcontrib><creatorcontrib>Schild, S.E.</creatorcontrib><creatorcontrib>Rades, D.</creatorcontrib><title>Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases</title><title>Strahlentherapie und Onkologie</title><addtitle>Strahlenther Onkol</addtitle><addtitle>Strahlenther Onkol</addtitle><description>Background
This study was performed to validate a scoring system published in 2008 to predict the survival of patients receiving whole-brain radiotherapy (WBRT) alone for brain metastases.
Methods
The scoring system included four independent prognostic factors: age, performance status, extracranial metastases, and interval between first diagnosis of cancer and WBRT. The score for each prognostic factor was determined by dividing the 6-month survival rate (in %) by 10. The total score represented the sum of the scores for each prognostic factor. Total scores ranged from 9–18 points, and patients were divided into four groups. In the present study, 350 new patients were evaluated in order to validate the previously developed score.
Results
In the present validation study, the 6-month survival rates were 8 % for patients with a score of 9–10 points (group A), 24 % for those with a score of 11–13 points (group B), 51 % for those with a score of 14–16 points (group C), and 82 % for those with scores of 17–18 points (group D), respectively (p < 0.001). In our previous study published in 2008, the 6-month survival rates were 6 %, 15 %, 43 %, and 76 %, respectively (p < 0.001). The comparisons between each of the four prognostic groups of both series did not reveal a significant difference.
Conclusion
In this study, the 6-month survival rates of the four prognostic groups were not significantly different from those of the preceding study. This demonstrates the validity and reproducibility of this score. The score can help select the appropriate treatment for the individual patient and help design prospective trials.</description><subject>Age Distribution</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - radiotherapy</subject><subject>Brain Neoplasms - secondary</subject><subject>Female</subject><subject>Germany - epidemiology</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Radiotherapy</subject><subject>Radiotherapy, Conformal - mortality</subject><subject>Reproducibility of Results</subject><subject>Risk Assessment - methods</subject><subject>Sensitivity and Specificity</subject><subject>Survival Analysis</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0179-7158</issn><issn>1439-099X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp1kEtLxDAQx4Mouj4-gBcJeI5OmrRpjiK-QPCi4i2kzcTtstusSdbFb2_XqngRBgZm_g_4EXLM4YwDqPMEAFXFgAsGAmomtsiES6EZaP2yTSbAlWaKl_Ue2U9pBsArqeUu2StEybUo6wnxz3beOZu70NPgqaVpFd-7dzunqQ0RqQ-RLoc39jnRHNFmdHTd5SldT8McWRNt19NoXRfyFKNdfnxZxvMCs03DYDokO97OEx597wPydH31eHnL7h9u7i4v7lkrVJFZW7VStLy0vPUNFKWsrS-FRu9ko1G6phZC-8YBKlSF13VVaa2VcnUtLS-cOCCnY-4yhrcVpmxmYRX7odJwUSqhpdYwqPioamNIKaI3y9gtbPwwHMyGrBnJmoGs2ZA1YvCcfCevmgW6X8cPykFQjII0vPpXjH-q_039BG0AhR8</recordid><startdate>20130501</startdate><enddate>20130501</enddate><creator>Dziggel, L.</creator><creator>Segedin, B.</creator><creator>Podvrsnik, N.H.</creator><creator>Oblak, I.</creator><creator>Schild, S.E.</creator><creator>Rades, D.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20130501</creationdate><title>Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases</title><author>Dziggel, L. ; Segedin, B. ; Podvrsnik, N.H. ; Oblak, I. ; Schild, S.E. ; Rades, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-c6c43c15a1cfb02548af539efd4b9e4db8339fbd0e7e72f986699977d884a12d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Age Distribution</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - radiotherapy</topic><topic>Brain Neoplasms - secondary</topic><topic>Female</topic><topic>Germany - epidemiology</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Radiotherapy</topic><topic>Radiotherapy, Conformal - mortality</topic><topic>Reproducibility of Results</topic><topic>Risk Assessment - methods</topic><topic>Sensitivity and Specificity</topic><topic>Survival Analysis</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dziggel, L.</creatorcontrib><creatorcontrib>Segedin, B.</creatorcontrib><creatorcontrib>Podvrsnik, N.H.</creatorcontrib><creatorcontrib>Oblak, I.</creatorcontrib><creatorcontrib>Schild, S.E.</creatorcontrib><creatorcontrib>Rades, D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Strahlentherapie und Onkologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dziggel, L.</au><au>Segedin, B.</au><au>Podvrsnik, N.H.</au><au>Oblak, I.</au><au>Schild, S.E.</au><au>Rades, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases</atitle><jtitle>Strahlentherapie und Onkologie</jtitle><stitle>Strahlenther Onkol</stitle><addtitle>Strahlenther Onkol</addtitle><date>2013-05-01</date><risdate>2013</risdate><volume>189</volume><issue>5</issue><spage>364</spage><epage>366</epage><pages>364-366</pages><issn>0179-7158</issn><eissn>1439-099X</eissn><abstract>Background
This study was performed to validate a scoring system published in 2008 to predict the survival of patients receiving whole-brain radiotherapy (WBRT) alone for brain metastases.
Methods
The scoring system included four independent prognostic factors: age, performance status, extracranial metastases, and interval between first diagnosis of cancer and WBRT. The score for each prognostic factor was determined by dividing the 6-month survival rate (in %) by 10. The total score represented the sum of the scores for each prognostic factor. Total scores ranged from 9–18 points, and patients were divided into four groups. In the present study, 350 new patients were evaluated in order to validate the previously developed score.
Results
In the present validation study, the 6-month survival rates were 8 % for patients with a score of 9–10 points (group A), 24 % for those with a score of 11–13 points (group B), 51 % for those with a score of 14–16 points (group C), and 82 % for those with scores of 17–18 points (group D), respectively (p < 0.001). In our previous study published in 2008, the 6-month survival rates were 6 %, 15 %, 43 %, and 76 %, respectively (p < 0.001). The comparisons between each of the four prognostic groups of both series did not reveal a significant difference.
Conclusion
In this study, the 6-month survival rates of the four prognostic groups were not significantly different from those of the preceding study. This demonstrates the validity and reproducibility of this score. The score can help select the appropriate treatment for the individual patient and help design prospective trials.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>23519358</pmid><doi>10.1007/s00066-013-0308-3</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0179-7158 |
| ispartof | Strahlentherapie und Onkologie, 2013-05, Vol.189 (5), p.364-366 |
| issn | 0179-7158 1439-099X |
| language | eng |
| recordid | cdi_proquest_journals_1357394990 |
| source | Springer Link |
| subjects | Age Distribution Aged Aged, 80 and over Brain Neoplasms - mortality Brain Neoplasms - radiotherapy Brain Neoplasms - secondary Female Germany - epidemiology Humans Incidence Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Radiotherapy Radiotherapy, Conformal - mortality Reproducibility of Results Risk Assessment - methods Sensitivity and Specificity Survival Analysis Survival Rate Treatment Outcome |
| title | Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T23%3A30%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validation%20of%20a%20survival%20score%20for%20patients%20treated%20with%20whole-brain%20radiotherapy%20for%20brain%20metastases&rft.jtitle=Strahlentherapie%20und%20Onkologie&rft.au=Dziggel,%20L.&rft.date=2013-05-01&rft.volume=189&rft.issue=5&rft.spage=364&rft.epage=366&rft.pages=364-366&rft.issn=0179-7158&rft.eissn=1439-099X&rft_id=info:doi/10.1007/s00066-013-0308-3&rft_dat=%3Cproquest_cross%3E2984986601%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c372t-c6c43c15a1cfb02548af539efd4b9e4db8339fbd0e7e72f986699977d884a12d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1357394990&rft_id=info:pmid/23519358&rfr_iscdi=true |